Slide 1: Felix: A unique device to treat male infertility
For personal use only ASX: MEM Felix A unique device to treat male infertility Alison Coutts Executive Chairman, Memphasys Limited www.memphasys.com.au 1
Slide 2: Disclaimer
Disclaimer For personal use only This presentation is not and does not form part of any offer, invitation or respective officers, directors, employees and agents, accept no responsibility recommendation in respect of securities. Any decision to buy or sell for any information provided in this presen
Slide 3: Pressing need for improvements in IVF
Pressing need for improvements in IVF For personal use only IVF: ▪ Expensive - up to $10,000 per try, average of 2.2 tries before successful pregnancy, success not always possible ▪ Physically and emotionally draining ▪ Increases risk of miscarriage, conceiving genetically impaired child What if the
Slide 4: Need to improve male fertility
Need to improve male fertility For personal use only Male Infertility ▪ A factor in ~50% of infertile couples ▪ Affects ~1/3rd of men over 40 ▪ Has been rapidly increasing for the past Sperm quality, few decades rather than quantity, - environmental and lifestyle factors ▪ No meaningful advances in
Slide 5: Human IVF market is large and rapidly growing
Human IVF market is large and rapidly growing For personal use only Key Human IVF market statistics Accessible Market1 IVF treatments market size US$9.3bn / IVF treatments 2012/2020 US$21.6bn including ICSI (Intra >$600 million Estimated no. IVF cycles pa ~6 million Cytoplasmic Sperm Injection) IVF
Slide 6: MEM's technology provides better chance of success
MEM’s technology provides better chance of success For personal use only ▪ Unique, patented IP, proven to work Special polymer membranes separate cells by size ▪ Developed with Prof John Aitken, world- renowned fertility expert ▪ Separates the ‘best’ quality, least DNA- damaged sperm1 from IVF semen
Slide 7: Memphasys' 'Felix' device has major advantages over current IVF sperm processing methods
Memphasys’ ‘Felix’ device has major advantages over current IVF sperm processing methods1 For personal use only Current methods ‘Felix’ device ▪ 30-40 minute, manual ✓ 3 minute, automated ▪ Damage DNA ✓ Gentle, no centrifuging, no cell damage ▪ Limited in types of sperm ✓ Can treat wide range of spe
Slide 8: Achievements and upcoming milestones
Achievements and upcoming milestones For personal use only 2008: Human births with earlier prototype device achieved Mid 2017: Prototype device with re-usable cartridges built 2018 (now): Development of clinical system with single-use cartridges commenced 2019: 10-15 international IVF Key Opinion Le
Slide 9: We've come a long way!
We’ve come a long way! For personal use only www.memphasys.com.au 9
Slide 10: Corporate Statistics
Corporate Statistics For personal use only Top 10 Shareholders Corporate Statistics 1 Mr Andrew Ernest Goodall 24.39% Shares on issue 363,922,478 2 Peters Investments Pty Ltd 18.32% Market capitalisation $18.2 million (@ 5 cents) 3 Ms Alison Coutts 16.21% Top 3 hold ~ 59% Top 10 hold ~ 72% www.memph
Slide 11: Investment highlights
Investment highlights For personal use only Unique, patented sperm separation technology • Developed with world-renowned reproduction specialist - Professor John Aitken Felix device for Human IVF • Proven to work; low technology risk • Need for better sperm processing for IVF • Large, fast-growing g
Slide 12: Thank you
For personal use only Thank you Alison Coutts Executive Chairman, Memphasys Ltd 30-32 Richmond Rd, Homebush NSW 2140 Australia Phone: +612 8415 7300 www.memphasys.com.au 12